Cholesterol remains one of the most debated biomarkers in cardiovascular medicine, yet many people still misunderstand what it actually tells us about metabolic health and disease risk. As research evolves, the conversation is shifting from simple cholesterol numbers toward deeper drivers of cardiometabolic dysfunction. In this episode of Extend, we sit down with Nick Norwitz, metabolic health researcher and physician scientist, to unpack the science behind cholesterol, insulin resistance, and cardiovascular risk. We break down the difference between LDL and ApoB, why insulin resistance may be a stronger predictor of heart disease, how statins work beyond cholesterol lowering, and what emerging research reveals about metabolic health, biomarkers, and individualized risk. We also explore how curiosity driven experimentation, data tracking, and deeper metabolic literacy can help people move beyond simplistic cholesterol narratives and better understand their own cardiometabolic health. Nick Norwitz is a physician scientist and metabolic health researcher who graduated valedictorian from Dartmouth College before earning a PhD in Human Metabolism from the University of Oxford and an MD from Harvard Medical School. Following a personal battle with inflammatory bowel disease, he became a leading voice in metabolic health education and the author of the widely read newsletter StayCuriousMetabolism.com. What We Discuss: (02:14) The biggest misconception about cholesterol, LDL, and cardiovascular risk (06:03) How sleep, inflammation, and plaque formation connect to heart disease (08:18) Why insulin resistance may predict cardiovascular risk more strongly than LDL (10:40) The atorvastatin study that showed suppressed GLP-1 levels (16:54) Statins, pleiotropy, and why lowering LDL is only part of the story (22:16) Coronary calcium scans and how imaging can change treatment decisions (24:48) The Lancet statin meta-analysis and how headlines distorted the findings (33:20) CoQ10, TUDCA, and supportive strategies for people taking statins (35:15) Ezetimibe, how it works, and why it may have neuroprotective potential (46:09) Bempedoic acid and how it compares with statins (51:47) PCSK9 inhibitors, pros and cons, and who may benefit most (54:20) ApoB versus LDL and why particle count matters (56:15) The Oreo experiment, lean mass hyper-responders, and individualized cholesterol responses (59:19) What to do after a high LDL result instead of automatically defaulting to a statin (1:02:00) Berberine, nattokinase, and other non-prescription options for cardiovascular support (1:06:03) The challenge of communicating nuance in health content online (1:10:18) Why personalized experimentation matters more than one-size-fits-all medicine (1:12:36) Lp(a), waist-to-hip ratio, and why cardiometabolic context changes risk Thank You to Our Sponsors: IM8: Try IM8 today with a 30-day money back guarantee. You can get 10% off your first order with code DRSHAH at https://im8health.com/discount/DRSHAH. Learn more about Dr. Shah: Website:drshah.com Clinic:next-health.com Instagram: darshanshahmd Learn more about Nick Norwitz: Newsletter: staycuriousmetabolism.com YouTube: nicknorwitzMDPhD Instagram: nicknorwitz Twitter: Nick Norwitz MD PhD

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related